Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QI-019A in Relapsed/Refractory Multiple Myeloma
NCT07429721Phase 1Recruiting
- Start
- Mar 2026
- Primary completion
- Jun 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of QI-019A in multiple myeloma (MM). Primary endpoints: Dose-Limiting Toxicity at 28 days and Adverse Events at 28 days. Started Mar 2026; status: recruiting.
02
Drugs
QI-019A
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07429721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07429721.